To determine the usefulness of positron emission tomography with fluoro-2-deoxyglucose (PET-FDG) in assessing mediastinal disease in patients with non-small-cell lung cancer (NSCLC) and to compare its yield to that of computed tomography (CT), we performed a prospective consecutive sample investigation in a university hospital and its related clinics. In 30 patients with NSCLC with clinical stage I (T1-2, NO, MO) disease, we compared the results of chest CT and PET-FDG with the findings at surgical exploration of the mediastinum. Seven (77%) of nine patients with surgically proven mediastinal metastasis were identified by the PET-FDG results, with four false-positives in 21 patients with negative lymph-node dissections (P=0 004). Using the results of pathologic examination of mediastinal lymph nodes as the criterion standard, the diagnostic sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) for PET-FDG imaging of mediastinal metastases were 78%, 81%, 80%, 64%, and 89%, respectively. The sensitivity, specificity, accuracy, PPV and NPV for chest CT in the detection of mediastinal metastasis were 56%, 86%, 77%, 63%, and 87%, respectively. CT and PET-FDG results agreed in 21 patients. The diagnostic accuracy of the combined imaging modalities was 90%. We concluded that mediastinal uptake ofFDG correlates with the extent of mediastinal involvement of NSCLC and may contribute to preoperative staging. PET-FDG imaging complements chest CT in the noninvasive evaluation of NSCLC, and strategies for its use merit further investigation. (Am J Respir Crit Care Med 1995;152:2090-6) The diagnosis and staging of lung cancer are everyday problems for chest physicians. The introductory article by Chin et all focuses on the detection of metastatic spread of non-small cell lung cancer to the mediastinal lymph nodes. They assessed two non-invasive imaging modalities -computed tomography (CT) and positron emission tomography (PET) with radiolabelled fluoro-2-deoxyglucose ("'FDG) -using histopathology of the nodes following surgical exploration of the mediastinum as the "gold standard". Radiographic computed tomography, as we know, gives excellent anatomical resolution (down to 1-0 mm or so with appropriate algorithms) but no cellular specificity apart from fat, water, and bone differentiation on the basis of Hounsfield numbers. For the assessment of malignancy in lymph nodes, CT relies solely on size. In a meta-analysis of 32 studies2 where a diameter of 5-10 mm was chosen as the threshold the accuracy of CT scanning was 0-75, increasing to 0-86 at >10 mm. However, many larger nodes (20-40 mm) may be negative if there has been chronic intrapulmonary infection. Magnetic resonance imaging is no better than CT scanning in this context.
The diagnosis and staging of lung cancer are everyday problems for chest physicians. The introductory article by Chin et all focuses on the detection of metastatic spread of non-small cell lung cancer to the mediastinal lymph nodes. They assessed two non-invasive imaging modalities -computed tomography (CT) and positron emission tomography (PET) with radiolabelled fluoro-2-deoxyglucose ("'FDG) -using histopathology of the nodes following surgical exploration of the mediastinum as the "gold standard". Radiographic computed tomography, as we know, gives excellent anatomical resolution (down to 1-0 mm or so with appropriate algorithms) but no cellular specificity apart from fat, water, and bone differentiation on the basis of Hounsfield numbers. For the assessment of malignancy in lymph nodes, CT relies solely on size. In a meta-analysis of 32 studies2 where a diameter of [5] [6] [7] [8] [9] [10] Imaging methods which are more cell or tissue specific are needed -for example, monoclonal antibodies which recognise tumour-specific cell surface antigens, or markers of an increased mitotic index (DNA probes such as "C-thymidine) or of protein turnover ("Cmethionine). Fortunately, a simpler solution is to hand. Cancer cells, along with phagocytes, have a very high glucose uptake for reasons which will be discussed later. 2-deoxyglucose (2-DOG) is an analogue of glucose whose intracellular metabolism is blocked when conversion to 2-DOG-6-phosphate occurs. If 2-DOG is radiolabelled with fluorine-18 (a positron emitting isotope with a physical half life of 110 minutes), the accumulation of radioactivity in any tissue reflects its "8FDG-6-phosphate content and its metabolic rate for glucose. 0 1-1 9) ) which makes the detection of neoplastic "hot spots"
easier.
The SUR is a relatively crude index because the tissue uptake has not reached a steady state 60 minutes after injection (fig 2A) when counting takes place. The Patlak plot ( fig 2B) discriminates between uninvolved and involved (that is, malignant) lesions better than the SUR24 -Patlak plot: 8-2 (3-8) ml/min/1 00 g for involved, 2 1 (1 7) for uninvolved; SUR: 6-9 (3-8) for involved, 2-7 (1 6) for uninvolved lung.24 Using a cut-off (benign versus malignant) for SUR of 3-5, and for the Patlak plot of 4 PET scans are compared with CT scans using histopathology ofnodes removed at thoracotomy as the "gold standard". The false negative (sensitivity) and false positive (specificity) rate is consistently lower for '8FDG-PET than for CT scanning. This is not surprising since the CT scan relies on size only, whereas '8FDG-PET measures a functional change.
In the introductory article by Chin et al' the malignant lymph nodes were assigned to a particular nodal station (for "8FDG-PET and CT scans and at surgery) according to the ATS map. 30 Although agreement between '8FDG-PET and CT nodal location and the surgically labelled station was poor, the nodal loci in each circumstance were generally within one level. Two groups have published co-registration images in which the "8FDG-PET and CT scans appear colour coded as overlays -an anatometabolic fusion image! Patz et al29 compared the specificity of '8FDG-PET scans for mediastinal versus hilar nodes (table 2). All '8FDG-PET positive mediastinal nodes were malignant, but seven out of 29 '9FDG-PET positive hilar nodes were "reactive" with significant inflammatory change (sinus histiocytosis).
18FDG-PET and extrapulmonary metastases Unsuspected lesions in the contralateral lung shown by '8FDG-PET scanning have led to cancellation ofsurgical exploration.' Lewis et al3' found extrathoracic '8FDG uptake in 11 of 34 patients with non-small cell lung cancer (all had a positive local '8FDG signal) including extrathoracic lymph nodes (5), brain (3), bone (2), and skin (1). These findings influenced subsequent management. Rege et al4 detected extrathoracic spread in three cases of lung cancer (brain (2), liver (1), pelvis (2)), and cervical and inguinal nodal involvement in a patient with positive hilar nodes due to Hodgkin's disease.
U "8FDG-6-phosphate is excreted in the urine. Whole body scanning shows regions of high activity in the bladder and renal calyces (especially with intrarenal hold-up). For a thorough examination of the pelvis, if indicated, urine must be voided or the bladder catheterised just before the pelvis is scanned.
Detection of recurrent tumour '8FDG-PET scanning has high sensitivity and specificity in the detection of recurrent cancer. In five studies232432-34 (219 patients) recurrent cancer was missed in only four of 139 cases (3%). The false positive rate was 15 of 80 cases (81% specificity) giving an overall accuracy of 91 %. The mean SUV in three studies2332 34 was 8-1 for cancer recurrence and 2-4 for no tumour. False positives occurred with radiation pneumonitis (1), macrophage accumulation around necrotic tissue (1), reactive mesothelial cells (2) , and acute inflammation (2). Frank et a133 found the sensitivity and specificity of 18FDG-PET to be 100% and 89%, respectively, compared with 67% and 85% for CT scanning, giving overall accuracies of 93% and 82%, respectively.
Technical aspects
The first study of lung cancer with "FDG-PET5 used an ECAT II (CTI, Knoxville) with a single ring of scintillation detectors. It was not a diagnostic machine. Figure  3 shows a series of images from the ECAT-ART scanner.
Future prospects FDG-PET will have a big impact in cancer staging and in monitoring the response to therapy. A single body scan with FDG-PET might replace some of the bone, CT, and MRI scans and the ultrasound imaging currently used in the examination of a patient with suspected or proven cancer. The FDG-PET scan could be very useful to the chest physician in the investigation of peripheral pulmonary nodules. The high negative predictive value of FDG-PET scanning means that a "cold" lesion is very unlikely to be malignant and can safely be watched without recourse to fine needle aspiration. 
